TCM
HTGM

Timpani Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Timpani Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,145
Closed -$1.04M – 114
2018
Q3 		$1.04M Buy
+1,145
New +$756K 0.3% 86

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Timpani Capital Management's HTGM Position: Q4 2018 in Review

Timpani Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2018, closing a stake of 1,145 shares — an estimated $1.04M sold.

Timpani Capital Management first reported a position in HTGM in Q3 2018 and held it in 1 quarter. The position peaked at $1.04M in Q3 2018. 48 funds tracked by Wall St. Rank hold HTGM as of Q4 2018.

  • Timpani Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Timpani Capital Management sold 1,145 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2018, an estimated $1.04M.
  • Timpani Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Timpani Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.04M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2018.

Based on Timpani Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.